Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]XY0206 in Healthy Male Volunteers
NCT06823232Phase 1Completed
- Sponsor
- Yiling Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XY0206 in acute myeloid leukemia (AML), sponsored by Yiling Pharmaceutical. Primary endpoints: Total radioactivity in excreta (urine and faeces) at 22 days and Radioactivity in blood sample at 22 days. Started Nov 2024; status: completed.
02
Drugs
XY0206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06823232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823232.